|Eleven dogs with cutaneous mast cell tumors (MCTs) were treated with surgery and iridium-192 (192Ir) interstitial brachytherapy.
Minimum tumor doses ranged from 47.2 to 63.3 Gy. Treated tumors were classified as grade II (n=7) or III (n=4).
Five dogs had recurrences with a median progression-free interval of 1391 days, and six dogs had no recurrence at a median follow-up time of 942 days.
Acute adverse effects were well tolerated, and late effects were mild. One dog developed a second tumor of a different cell type in the radiation treatment field.
Source: Nicole C. Northrup, Royce E. Roberts, Todd W. Harrell, Karen L. Allen, Elizabeth W. Howerth, Tracy L. Gieger (2004): Iridium-192 Interstitial Brachytherapy as Adjunctive Treatment for Canine Cutaneous Mast Cell Tumors. In: Journal of the American Animal Hospital Association 40:309-315 (2004)
Tell a friend
Send this article